clinical trial · NCT05143229
Alpelisib And Sacituzumab Govitecan For Treatment Of Breast Cancer
University of Kansas Medical Center·phase1·active not recruiting·n = 18
Breast CancerAlpelisibSacituzumab govitecan
brief summary
This study evaluates the safety and efficacy of sacituzumab govitecan plus alpelisib for treatment of metastatic or locally recurrent HER2-negative breast cancer.
started
Mar 28, 2022
primary completion
Jan 28, 2025
completion
Dec 1, 2026
last updated
May 1, 2026
official title
Phase I Trial Of Alpelisib Plus Sacituzumab Govitecan In Patients With Metastatic Or Locally Recurrent HER2-Negative Breast Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol